Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Both USA and vaccine focus are critical to solvency

Richard Hatchett, 6-29-2021, CEO of the Coalition for Epidemic Preparedness Innovation, CEPI & former BARDA, acting director U.S. Biomedical Advanced Research and Development Authority, https://www.csis.org/analysis/cepi-20-critical-inflection-point, "CEPI 2.0: A Critical Inflection Point," No Publication (ermo/sms, Acc:6-20-2022)

Richard Hatchett, M.D.: Well, I think there’s basically three, you know, areas that there’s good alignment. I mean, there’s good alignment around the scientific agenda. I mean, our adoption of the—you know, focusing on the prototype pathogens, you know, we’ve drawn from the National Institute of Allergy and Infectious Diseases. Barney Graham and colleagues at the Vaccine Research Center have evolved that concept and, you know, have promulgated it. And we think they’re right. So the scientific approach, there’s already alignment. We’re ready to work hand-in-hand with the major science funding agencies within the U.S. to divide and conquer what is a very big R&D agenda.

There’s a political aspect, a political moment for the United States in terms of sort of its return to multilateral efforts. And I think, you know, this is a good opportunity for the U.S. to be forward-looking, to, you know, take a progressive and longer-term view, and to do that in a way that invites other global partners to participate. And CEPI, as a—you know, I mean, we aren’t a country. We don’t have a point of view. We’re just trying to solve one particular problem. And I think it’s a good way for the U.S. to join with the 25 or so other countries that are supporting CEPI in a global effort around countermeasures development for epidemic and pandemic threats.

And then finally, I think there’s an argument from self-interest, which is that if we see future epidemic or pandemic threats, the U.S. government has dual responsibilities. They have a responsibility to their own population, obviously, that will always be primary. But CEPI I think offers an opportunity for the U.S. to support international efforts and to support global equity simultaneously and in parallel, as—in future responses—as they’re addressing the needs of the U.S. population. So I think the value proposition that CEPI can bring in terms of, you know, a partnership with the U.S. are, you know, operating on multiple levels. And they’re all aligned with U.S. interests.

Sign in to recut, update, or save this card.